Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.

Also called NCT02354222

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 154 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02354222
Other papers using this trial's data
  • Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study Diabetes, obesity & metabolism, 2018-02 DOI, PubMed 28786530, PMC5846888 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02354222. Randomized; quadruple masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-02 (actual). Results posted on 2018-08-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Canagliflozin
Intervention (Drug)
Teneligliptin
Intervention (Drug)
Placebo
Lead sponsor
Tanabe Pharma Corporation (class: industry)

Record details

Record id
cardio:ct-nct02354222
Content hash
cb418f599778813ad53d250fd591c6d4a9eb2c150783daddb8f28bbab8fbb1b3